The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Understanding biomarkers and patient eligibility for CAR T cell therapies in diffuse large B cell lymphoma.
Featured:
Kieron Dunleavy
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
Which subtype of B-cell lymphoma shows significant improvement in patient event-free survival after CAR T-cell therapy in numerous studies?
A
B
C
D
Video series
Here, we share a presentation by Kieron Dunleavy, GW Cancer Center, Washington D.C., US, on biomarkers and patient eligibility for chimeric antigen receptor T-cell (CAR T-cell) therapies in diffuse large B cell lymphoma (DLBCL).
In this presentation, Dunleavy discusses key clinical trials and subtypes of DLBCL that are associated with mutations which may represent therapeutic biomarkers (Figure 1), as well as key factors that impact CAR T-cell therapy response, specifically in high grade B-cell lymphoma (Figure 2).
Figure 1. Molecular biology of DLBCL and their candidate drug targets*
*Adapted from Level, et al.1
Figure 2. Impact of high-grade B-cell lymphoma on efficacy of CAR T-cells*
*Adapted from Ali A, et al.2 Created with BioRender.com
Watch or download the presentation to learn more about CAR T-cell therapy in patients with DLBCL, including:
- The currently approved therapies and clinical trials associated with these CAR T-cell therapies
- Key factors that impact CAR T-cell therapy response
- The subtypes of DLBCL and their World Health Organization (WHO) and International Consensus Criteria 2022 classifications
- The impact of disease characteristics on the outcome of treatment assessed in ZUMA-7 (NCT03391466) compared with TRANSFORM (NCT03575351).
Key points
- Disease characteristics, tumor biological characteristics, tumor microenvironment and interval response have been shown to impact CAR T-cell response.
- The ZUMA-7 and TRANSFORM clinical trials showed that CAR T-cell therapy was more advantageous compared with autologous stem cell transplant.
- There are several genetic subtypes of DLBCL with hallmark genetic features that can set the stage for candidate drug targeting.
- Older patients (≥65 years old), patients with activated B-cell cases, or high grade B-cell lymphomas had particularly good survival outcomes compared to other disease characteristics.3,4
- High grade B-cell lymphoma has been shown to have better survival outcomes post CAR T-cell therapy compared with other DLBCL subtypes, both in clinical trials and real-world evidence studies.1
This activity was supported through an educational grant from Bristol Myers Squibb.
References
More from this series:
